Visionary Holdings Launches Medical-Grade Stem Cell Anti-Aging Product Line in Asia
Key Insights
Visionary Holdings (Nasdaq: GV) has officially launched its medical-grade stem cell anti-aging product line targeting Chinese mainland and broader Asian markets through its wholly owned subsidiary.
The product portfolio includes three major categories: Comprehensive Regenerative Package with mesenchymal stem cells and NK cell therapy, Precision Repair Package with targeted stem cell therapy, and Premium Personalized Program with full-genome sequencing.
The launch follows GV's strategic partnership and global technology licensing agreement with Jiangsu Yike Regenerative Medicine Co., Ltd., marking the transition from R&D collaboration to commercial implementation.
Visionary Holdings Inc. (search) (Nasdaq: GV) has officially launched its medical-grade stem cell anti-aging product line through its wholly owned subsidiary, Visionary Health Technology Group Limited, initially targeting the Chinese mainland and broader Asian markets. The launch represents a significant milestone following the company's entry into the stem cell and medical aesthetics sector earlier this year.
Product Portfolio and Technology Integration
The anti-aging product portfolio encompasses three major categories designed for different client segments. The flagship Life Rejuvenation Program combines mesenchymal stem cells, NK cell therapy, and AI-based diagnostics, specifically designed for entrepreneurs and high-net-worth individuals. The Precision Repair Package integrates targeted stem cell therapy and DFPP blood purification for clients with specific degenerative or chronic conditions. The Premium Personalized Program includes full-genome sequencing, dual-institution medical consultations, and annual customized health management for ultra-high-net-worth clients.
The product launch marks GV's transition from R&D collaboration to tangible market implementation following its global licensing agreement with Jiangsu Yike Regenerative Medicine Co., Ltd. GV has integrated Yike's proprietary regenerative technologies into a comprehensive suite of personalized anti-aging and cellular rejuvenation solutions, covering stem cell therapy, NK cell revitalization, AI-based health assessment, and nano-delivery systems.
Strategic Market Expansion
The new products will be operated through GV's Asia-Pacific headquarters in Hong Kong, initially launching across Hong Kong, Singapore, and the Chinese mainland to provide premium, customized health solutions for high-end clients. The company plans to advance its commercialization strategy through several key initiatives, including establishing a joint venture production and clinical application base to enable localized manufacturing and validation of stem cell products.
GV intends to build a cross-border sales and distribution network covering mainland China, Hong Kong, and Southeast Asia, while expanding into Canada, the United States, and Mexico. The company also plans to partner with premium medical and aesthetic institutions to jointly develop branded clinics and anti-aging experience centers.
Corporate Transformation and Leadership
Visionary Holdings has successfully completed a strategic transformation, establishing anti-aging high-end medical aesthetics as its core business focus, with its traditional education business now serving as a supplementary division. Following the Annual General Meeting held on October 29, 2025, a new nine-member Board of Directors was elected, with William T. Chai serving as Chairman and Donald M. Kealey as Vice Chairman.
The executive leadership team includes Xiyong Hou as Chief Executive Officer, Jun Huang as Co-CEO, Robert Jay Lees as Chief Operating Officer, and Katy Liu as Chief Financial Officer. Key milestones in the transformation include two major partnerships established in September 2025: a global R&D partnership with Jiangsu Yike Regenerative Medicine Technology Co., Ltd., and a joint venture with Anhui Weikang Kangling Medical Technology Co., Ltd. to build an "Anti-Aging High-End Medical Aesthetics and Health Center" at the company's property in Toronto, Canada.
Management Perspective
"The official launch of GV's stem cell-based anti-aging products marks an important milestone in transforming our technological assets into tangible commercial value," said Xiyong Hou, CEO of Visionary Holdings. "Since entering into our strategic partnership and global licensing agreement with Yike, GV has successfully advanced from technology development to market-ready products."
Hou emphasized that as Asia continues to be the fastest-growing market for regenerative aesthetics, the launch not only opens new revenue streams for GV but also establishes a solid foundation for the company's leadership in longevity and cellular rejuvenation technologies. The company expects this product line to serve as a new driver of profitability in upcoming fiscal years and to further strengthen GV's visibility and positioning in the global capital markets.